Targeting dendritic cell function during systemic autoimmunity to restore tolerance

International Journal of Molecular Sciences

Volumn 15, Issue 9, 2014, Pages 16381-16417

  Mackern Oberti, Juan P ^a   Vega, Fabián ^b   Llanos, Carolina ^b   Bueno, Susan M ^a,c   Kalergis, Alexis M ^a,b,c  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c Centre National de la Recherche Scientifique   (France)

Author keywords

Autoimmunity; Dendritic cells; Therapy; Tolerance

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; ACETYLSALICYLIC ACID; ALPHA INTERFERON; ATACICEPT; B CELL ACTIVATING FACTOR; B7 ANTIGEN; BELIMUMAB; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CD137 ANTIGEN; CD137 LIGAND; CD70 ANTIGEN; CD86 ANTIGEN; COLECALCIFEROL; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DEXAMETHASONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE T CELL COSTIMULATOR LIGAND; INTERLEUKIN 10; INTERLEUKIN 6; PHOSPHORYL LIPID A; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; RAPAMYCIN; ROSIGLITAZONE; TOCILIZUMAB; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; 3-(4-METHYLPHENYLSULFONYL)-2-PROPENENITRILE; ANTIINFLAMMATORY AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NITRILE; SULFONE;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; BIOLOGICAL THERAPY; CELL FUNCTION; CELL INTERACTION; CELL MATURATION; DENDRITIC CELL; GENE THERAPY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOTHERAPY; METABOLIC REGULATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; AUTOIMMUNE DISEASES; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PATHOLOGY; T LYMPHOCYTE;

ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CHOLECALCIFEROL; DENDRITIC CELLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNE TOLERANCE; NITRILES; SULFONES; T-LYMPHOCYTES;

EID: 84907212387     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150916381     Document Type: Review

References (233)

1. Gratz, I.K.; Rosenblum, M.D.; Maurano, M.M.; Paw, J.S.; Truong, H.A.; Marshak-Rothstein, A.; Abbas, A.K. Cutting edge: Self-antigen controls the balance between effector and regulatory T cells in peripheral tissues. J. Immunol. 2014, 192, 1351-1355.
2. Luo, X.; Yang, W.; Ye, D.-Q.; Cui, H.; Zhang, Y.; Hirankarn, N.; Qian, X.; Tang, Y.; Lau, Y.L.; de Vries, N.; et al. A functional variant in microrna-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus. PLoS Genet. 2011, 7, e1002128.
3. Ginzler, E.M.; Dooley, M.A.; Aranow, C.; Kim, M.Y.; Buyon, J.; Merrill, J.T.; Petri, M.; Gilkeson, G.S.; Wallace, D.J.; Weisman, M.H.; et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 2005, 353, 2219-2228.
4. Perez, V.L.; van Parijs, L.; Biuckians, A.; Zheng, X.X.; Strom, T.B.; Abbas, A.K. Induction of peripheral T cell tolerance in vivo requires ctla-4 engagement. Immunity 1997, 6, 411-417.
5. Bernatsky, S.; Boivin, J.F.; Joseph, L.; Manzi, S.; Ginzler, E.; Gladman, D.D.; Urowitz, M.; Fortin, P.R.; Petri, M.; Barr, S.; et al. Mortality in systemic lupus erythematosus. Arthritis Rheumatol. 2006, 54, 2550-2557.
6. Carreño, L.J.; Pacheco, R.; Gutierrez, M.A.; Jacobelli, S.; Kalergis, A.M. Disease activity in systemic lupus erythematosus is associated with an altered expression of low-affinity fcγ receptors and costimulatory molecules on dendritic cells. Immunology 2009, 128, 334-341.
7. Crispin, J.C.; Kyttaris, V.C.; Terhorst, C.; Tsokos, G.C. T cells as therapeutic targets in sle. Nat. Rev. Rheumatol. 2010, 6, 317-325.
8. Gaipl, U.S.; Munoz, L.E.; Grossmayer, G.; Lauber, K.; Franz, S.; Sarter, K.; Voll, R.E.; Winkler, T.; Kuhn, A.; Kalden, J.; et al. Clearance deficiency and systemic lupus erythematosus (SLE). J. Autoimmun. 2007, 28, 114-121.
9. Gerl, V.; Lischka, A.; Panne, D.; Großmann, P.; Berthold, R.; Hoyer, B.F.; Biesen, R.; Bruns, A.; Alexander, T.; Jacobi, A.; et al. Blood dendritic cells in systemic lupus erythematosus exhibit altered activation state and chemokine receptor function. Ann. Rheum. Dis. 2010, 69, 1370-1377.
10. Ding, D.; Mehta, H.; McCune, W.J.; Kaplan, M.J. Aberrant phenotype and function of myeloid dendritic cells in systemic lupus erythematosus. J. Immunol. 2006, 177, 5878-5889.
11. Schwarz, E.; Ritchlin, C. Clinical development of anti-rankl therapy. Arthritis Res. Ther. 2007, 9, S7.
12. Orban, T.; Bundy, B.; Becker, D.J.; DiMeglio, L.A.; Gitelman, S.E.; Goland, R.; Gottlieb, P.A.; Greenbaum, C.J.; Marks, J.B.; Monzavi, R.; et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled trial. Lancet 2011, 378, 412-419.
13. Houssiau, F.; Ginzler, E. Current treatment of lupus nephritis. Lupus 2008, 17, 426-430.
14. Hahn, B.H. Belimumab for systemic lupus erythematosus. N. Engl. J. Med. 2013, 368, 1528-1535.
15. Navarra, S.V.; Guzmán, R.M.; Gallacher, A.E.; Hall, S.; Levy, R.A.; Jimenez, R.E.; Li, E.K.M.; Thomas, M.; Kim, H.-Y.; León, M.G.; et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 2010, 377, 721-731.
16. Furie, R.; Petri, M.; Zamani, O.; Cervera, R.; Wallace, D.J.; Tegzova, D.; Sanchez-Guerrero, J.; Schwarting, A.; Merrill, J.T.; Chatham, W.W.; et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2011, 63, 3918-3930.
17. Lee, J.-H.; Kim, T.-H.; Park, H.E.; Lee, E.G.; Jung, N.-C.; Song, J.-Y.; Seo, H.G.; Seung, K.-B.; Chang, K.; Lim, D.-S. Myosin-primed tolerogenic dendritic cells ameliorate experimental autoimmune myocarditis. Cardiovasc. Res. 2014, 101, 203-210.
18. Mukhopadhaya, A.; Hanafusa, T.; Jarchum, I.; Chen, Y.-G.; Iwai, Y.; Serreze, D.V.; Steinman, R.M.; Tarbell, K.V.; DiLorenzo, T.P. Selective delivery of β cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8+ T cells in nod mice. Proc. Natl. Acad. Sci. USA 2008, 105, 6374-6379.
19. Dufait, I.; Liechtenstein, T.; Lanna, A.; Bricogne, C.; Laranga, R.; Padella, A.; Breckpot, K.; Escors, D. Retroviral and lentiviral vectors for the induction of immunological tolerance. Scientifica 2012, 2012, doi:10.6064/2012/694137.
20. Anderson, M.S.; Venanzi, E.S.; Chen, Z.; Berzins, S.P.; Benoist, C.; Mathis, D. The cellular mechanism of aire control of T cell tolerance. Immunity 2005, 23, 227-239.
21. Carreno, L.J.; Gonzalez, P.A.; Kalergis, A.M. Modulation of T cell function by TCR/pMHC binding kinetics. Immunobiology 2006, 211, 47-64.
22. Iruretagoyena, M.I.; Wiesendanger, M.; Kalergis, A.M. The dendritic cell-T cell synapse as a determinant of autoimmune pathogenesis. Curr. Pharm. Des. 2006, 12, 131-147.
23. Kalergis, A.M. Modulation of T cell immunity by TCR/pMHC dwell time and activating/inhibitory receptor pairs on the antigen-presenting cell. Curr. Pharm. Des. 2003, 9, 233-244.
24. Banchereau, J.; Steinman, R.M. Dendritic cells and the control of immunity. Nature 1998, 392, 245-252.
25. Grewal, I.S.; Foellmer, H.G.; Grewal, K.D.; Xu, J.; Hardardottir, F.; Baron, J.L.; Janeway, C.A., Jr.; Flavell, R.A. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science 1996, 273, 1864-1867.
26. Linsley, P.S.; Brady, W.; Grosmaire, L.; Aruffo, A.; Damle, N.K.; Ledbetter, J.A. Binding of the B cell activation antigen b7 to CD28 costimulates T cell proliferation and interleukin 2 mrna accumulation. J. Exp. Med. 1991, 173, 721-730.
27. Hubo, M.; Trinschek, B.; Kryczanowsky, F.; Tüttenberg, A.; Steinbrink, K.; Jonuleit, H. Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells. Front. Immunol. 2013, 4, 82.
28. Crispin, J.C.; Vargas-Rojas, M.I.; Monsivais-Urenda, A.; Alcocer-Varela, J. Phenotype and function of dendritic cells of patients with systemic lupus erythematosus. Clin. Immunol. 2012, 143, 45-50.
29. Ito, T.; Wang, Y.-H.; Duramad, O.; Hori, T.; Delespesse, G.J.; Watanabe, N.; Qin, F.X.-F.; Yao, Z.; Cao, W.; Liu, Y.-J. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J. Exp. Med. 2005, 202, 1213-1223.
30. Gaspal, F.; Withers, D.; Saini, M.; Bekiaris, V.; McConnell, F.M.; White, A.; Khan, M.; Yagita, H.; Walker, L.S.K.; Anderson, G.; et al. Abrogation of CD30 and OX40 signals prevents autoimmune disease in foxp3-deficient mice. J. Exp. Med. 2011, 208, 1579-1584.
31. Gerritse, K.; Laman, J.D.; Noelle, R.J.; Aruffo, A.; Ledbetter, J.A.; Boersma, W.J.; Claassen, E. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. USA 1996, 93, 2499-2504.
32. Bagenstose, L.M.; Agarwal, R.K.; Silver, P.B.; Harlan, D.M.; Hoffmann, S.C.; Kampen, R.L.; Chan, C.-C.; Caspi, R.R. Disruption of CD40/CD40-ligand interactions in a retinal autoimmunity model results in protection without tolerance. J. Immunol. 2005, 175, 124-130.
33. Witsch, E.J.; Peiser, M.; Hutloff, A.; Büchner, K.; Dorner, B.G.; Jonuleit, H.; Mages, H.W.; Kroczek, R.A. ICOS and CD28 reversely regulate IL-10 on re-activation of human effector T cells with mature dendritic cells. Eur. J. Immunol. 2002, 32, 2680-2686.
34. Yoshinaga, S.K.; Whoriskey, J.S.; Khare, S.D.; Sarmiento, U.; Guo, J.; Horan, T.; Shih, G.; Zhang, M.; Coccia, M.A.; Kohno, T.; et al. T-cell co-stimulation through B7RP-1 and ICOS. Nature 1999, 402, 827-832.
35. Kopf, M.; Coyle, A.J.; Schmitz, N.; Barner, M.; Oxenius, A.; Gallimore, A.; Gutierrez-Ramos, J.-C.; Bachmann, M.F. Inducible costimulator protein (ICOS) controls T helper cell subset polarization after virus and parasite infection. J. Exp. Med. 2000, 192, 53-62.
36. Sim, G.C.; Martin-Orozco, N.; Jin, L.; Yang, Y.; Wu, S.; Washington, E.; Sanders, D.; Lacey, C.; Wang, Y.; Vence, L.; et al. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J. Clin. Investig. 2014, 124, 99-110.
37. Prevot, N.; Briet, C.; Lassmann, H.; Tardivel, I.; Roy, E.; Morin, J.; Mak, T.W.; Tafuri, A.; Boitard, C. Abrogation of ICOS/ICOS ligand costimulation in nod mice results in autoimmune deviation toward the neuromuscular system. Eur. J. Immunol. 2010, 40, 2267-2276.
38. Waterhouse, P.; Penninger, J.M.; Timms, E.; Wakeham, A.; Shahinian, A.; Lee, K.P.; Thompson, C.B.; Griesser, H.; Mak, T.W. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995, 270, 985-988.
39. Podojil, J.; Miller, S. Targeting the B7 family of co-stimulatory molecules. BioDrugs 2013, 27, 1-13.
40. Fife, B.T.; Griffin, M.D.; Abbas, A.K.; Locksley, R.M.; Bluestone, J.A. Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J. Clin. Investig. 2006, 116, 2252-2261.
41. Picchianti Diamanti, A.; Rosado, M.M.; Scarsella, M.; Germano, V.; Giorda, E.; Cascioli, S.; Laganà, B.; D'Amelio, R.; Carsetti, R. Abatacept (CTLA4-Ig) improves B cell function and treg inhibitory capacity in rheumatoid arthritis patients non responding to anti-tnf-alpha agents. Clin. Exp. Immunol. 2014, doi:10.1111/cei.12367.
42. Jin, Y.; Qu, A.; Wang, G.M.; Hao, J.; Gao, X.; Xie, S. Simultaneous stimulation of fas-mediated apoptosis and blockade of costimulation prevent autoimmune diabetes in mice induced by multiple low-dose streptozotocin. Gene Ther. 2004, 11, 982-991.
43. Feng, Y.G.; Jin, Y.Z.; Zhang, Q.Y.; Hao, J.; Wang, G.M.; Xie, S.S. CTLA4-FAS ligand gene transfer mediated by adenovirus induce long-time survival of murine cardiac allografts. Transplant. Proc. 2005, 37, 2379-2381.
44. Ikawa, K.; Araki, H.; Tsujino, Y.; Hayashi, Y.; Igarashi, K.; Hatada, Y.; Hagihara, H.; Ozawa, T.; Ozaki, K.; Kobayashi, T.; et al. Hyperexpression of the gene for a bacillus alpha-amylase in bacillus subtilis cells: Enzymatic properties and crystallization of the recombinant enzyme. Biosci. Biotechnol. Biochem. 1998, 62, 1720-1725.
45. Yamazaki, T.; Akiba, H.; Iwai, H.; Matsuda, H.; Aoki, M.; Tanno, Y.; Shin, T.; Tsuchiya, H.; Pardoll, D.M.; Okumura, K.; et al. Expression of programmed death 1 ligands by murine T cells and apc. J. Immunol. 2002, 169, 5538-5545.
46. Keir, M.E.; Francisco, L.M.; Sharpe, A.H. PD-1 and its ligands in T-cell immunity. Curr. Opin. Immunol. 2007, 19, 309-314.
47. Dilek, N.; Poirier, N.; Hulin, P.; Coulon, F.; Mary, C.; Ville, S.; Vie, H.; Clémenceau, B.; Blancho, G.; Vanhove, B. Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells. PLoS One 2013, 8, e83139.
48. Francisco, L.M.; Salinas, V.H.; Brown, K.E.; Vanguri, V.K.; Freeman, G.J.; Kuchroo, V.K.; Sharpe, A.H. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 2009, 206, 3015-3029.
49. Yogev, N.; Frommer, F.; Lukas, D.; Kautz-Neu, K.; Karram, K.; Ielo, D.; von Stebut, E.; Probst, H.-C.; van den Broek, M.; Riethmacher, D.; et al. Dendritic cells ameliorate autoimmunity in the cns by controlling the homeostasis of PD-1 receptor+ regulatory T cells. Immunity 2012, 37, 264-275.
50. Schreiner, B.; Bailey, S.L.; Shin, T.; Chen, L.; Miller, S.D. PD-1 ligands expressed on myeloid-derived apc in the CNS regulate T-cell responses in eae. Eur. J. Immunol. 2008, 38, 2706-2717.
51. Latchman, Y.E.; Liang, S.C.; Wu, Y.; Chernova, T.; Sobel, R.A.; Klemm, M.; Kuchroo, V.K.; Freeman, G.J.; Sharpe, A.H. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc. Natl. Acad. Sci. USA 2004, 101, 10691-10696.
52. Nishimura, H.; Nose, M.; Hiai, H.; Minato, N.; Honjo, T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an itim motif-carrying immunoreceptor. Immunity 1999, 11, 141-151.
53. Watanabe, N.; Gavrieli, M.; Sedy, J.R.; Yang, J.; Fallarino, F.; Loftin, S.K.; Hurchla, M.A.; Zimmerman, N.; Sim, J.; Zang, X.; et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat. Immunol. 2003, 4, 670-679.
54. Oya, Y.; Watanabe, N.; Owada, T.; Oki, M.; Hirose, K.; Suto, A.; Kagami, S.-I.; Nakajima, H.; Kishimoto, T.; Iwamoto, I.; et al. Development of autoimmune hepatitis-like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator. Arthritis Rheumatol. 2008, 58, 2498-2510.
55. Hitoshi, Y.; Lorens, J.; Kitada, S.-I.; Fisher, J.; LaBarge, M.; Ring, H.Z.; Francke, U.; Reed, J.C.; Kinoshita, S.; Nolan, G.P. Toso, a cell surface, specific regulator of FAS-induced apoptosis in T cells. Immunity 1998, 8, 461-471.
56. Brenner, D.; Brüstle, A.; Lin, G.H.Y.; Lang, P.A.; Duncan, G.S.; Knobbe-Thomsen, C.B.; St. Paul, M.; Reardon, C.; Tusche, M.W.; Snow, B.; et al. Toso controls encephalitogenic immune responses by dendritic cells and regulatory T cells. Proc. Natl. Acad. Sci. USA 2014, 111, 1060-1065.
57. Vinay, D.S.; Choi, J.H.; Kim, J.D.; Choi, B.K.; Kwon, B.S. Role of endogenous 4-1BB in the development of systemic lupus erythematosus. Immunology 2007, 122, 394-400.
58. Sun, Y.; Chen, H.M.; Subudhi, S.K.; Chen, J.; Koka, R.; Chen, L.; Fu, Y.-X. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat. Med. 2002, 8, 1405-1413.
59. Wakkach, A.; Cottrez, F.; Groux, H. Differentiation of regulatory T cells 1 is induced by cd2 costimulation. J. Immunol. 2001, 167, 3107-3113.
60. Pasare, C.; Medzhitov, R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003, 299, 1033-1036.
61. Wan, S.; Xia, C.; Morel, L. Il-6 produced by dendritic cells from lupus-prone mice inhibits CD4+CD25+ T cell regulatory functions. J. Immunol. 2007, 178, 271-279.
62. Bondanza, A.; Zimmermann, V.S.; dell'Antonio, G.; Dal Cin, E.; Capobianco, A.; Sabbadini, M.G.; Manfredi, A.A.; Rovere-Querini, P. Cutting edge: Dissociation between autoimmune response and clinical disease after vaccination with dendritic cells. J. Immunol. 2003, 170, 24-27.
63. Ma, L.; Chan, K.W.; Trendell-Smith, N.J.; Wu, A.; Tian, L.; Lam, A.C.; Chan, A.K.; Lo, C.K.; Chik, S.; Ko, K.H.; et al. Systemic autoimmune disease induced by dendritic cells that have captured necrotic but not apoptotic cells in susceptible mouse strains. Eur. J. Immunol. 2005, 35, 3364-3375.
64. Georgiev, M.; Agle, L.M.A.; Chu, J.L.; Elkon, K.B.; Ashany, D. Mature dendritic cells readily break tolerance in normal mice but do not lead to disease expression. Arthritis Rheumatol. 2005, 52, 225-238.
65. Mackay, F.; Woodcock, S.A.; Lawton, P.; Ambrose, C.; Baetscher, M.; Schneider, P.; Tschopp, J.; Browning, J.L. Mice transgenic for baff develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 1999, 190, 1697-1710.
66. Vincent, F.; Northcott, M.; Hoi, A.; Mackay, F.; Morand, E. Association of serum B cell activating factor from the tumour necrosis factor family (baff) and a proliferation-inducing ligand (april) with central nervous system and renal disease in systemic lupus erythematosus. Lupus 2013, 22, 873-884.
67. Kim, J.Y.; Yang, Y.; Moon, J.-S.; Lee, E.Y.; So, S.H.; Lee, H.-S.; Park, K.D.; Choi, Y.-C. Serum baff expression in patients with myasthenia gravis. J. Neuroimmunol. 2008, 199, 151-154.
68. Vannucchi, G.; Covelli, D.; Curro, N.; Dazzi, D.; Maffini, A.; Campi, I.; Bonara, P.; Guastella, C.; Pignataro, L.; Ratiglia, R.; et al. Serum baff concentrations in patients with graves' disease and orbitopathy before and after immunosuppressive therapy. J. Clin. Endocrinol. Metab. 2012, 97, E755-E759.
69. Nagai, M.; Hirayama, K.; Ebihara, I.; Shimohata, H.; Kobayashi, M.; Koyama, A. Serum levels of baff and april in myeloperoxidase anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis: Association with disease activity. Nephron Clin. Pract. 2011, 118, c339-c345.
70. Xin, G.; Cui, Z.; Su, Y.; Xu, L.-X.; Zhao, M.-H.; Li, K.-S. Serum baff and april might be associated with disease activity and kidney damage in patients with anti-glomerular basement membrane disease. Nephrology 2013, 18, 209-214.
71. Gross, J.A.; Dillon, S.R.; Mudri, S.; Johnston, J.; Littau, A.; Roque, R.; Rixon, M.; Schou, O.; Foley, K.P.; Haugen, H.; et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: Impaired B cell maturation in mice lacking BLYS. Immunity 2001, 15, 289-302.
72. Gross, J.A.; Johnston, J.; Mudri, S.; Enselman, R.; Dillon, S.R.; Madden, K.; Xu, W.; Parrish-Novak, J.; Foster, D.; Lofton-Day, C.; et al. Taci and bcma are receptors for a tnf homologue implicated in B-cell autoimmune disease. Nature 2000, 404, 995-999.
73. Ginzler, E.; Wax, S.; Rajeswaran, A.; Copt, S.; Hillson, J.; Ramos, E.; Singer, N. Atacicept in combination with mmf and corticosteroids in lupus nephritis: Results of a prematurely terminated trial. Arthritis Res. Ther. 2012, 14, R33.
74. Gorelik, L.; Gilbride, K.; Dobles, M.; Kalled, S.L.; Zandman, D.; Scott, M.L. Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J. Exp. Med. 2003, 198, 937-945.
75. Jego, G.; Palucka, A.K.; Blanck, J.-P.; Chalouni, C.; Pascual, V.; Banchereau, J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003, 19, 225-234.
76. Nishimoto, N.; Kishimoto, T. Interleukin 6: From bench to bedside. Nat. Clin. Pract. Rheum. 2006, 2, 619-626.
77. Yokota, S.; Imagawa, T.; Mori, M.; Miyamae, T.; Takei, S.; Iwata, N.; Umebayashi, H.; Murata, T.; Miyoshi, M.; Tomiita, M.; et al. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. J. Rheumatol. 2014, 41, 759-767.
78. Conaghan, P.G.; Peterfy, C.; Olech, E.; Kaine, J.; Ridley, D.; DiCarlo, J.; Friedman, J.; Devenport, J.; Troum, O. The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: Results from the ACT-RAY MRI substudy. Ann. Rheum. Dis. 2014, 73, 810-816.
79. Yao, X.; Huang, J.; Zhong, H.; Shen, N.; Faggioni, R.; Fung, M.; Yao, Y. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol. Ther. 2014, 141, 125-139.
80. Harigai, M.; Kawamoto, M.; Hara, M.; Kubota, T.; Kamatani, N.; Miyasaka, N. Excessive production of IFN-γ in patients with systemic lupus erythematosus and its contribution to induction of b lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13b. J. Immunol. 2008, 181, 2211-2219.
81. Litinskiy, M.B.; Nardelli, B.; Hilbert, D.M.; He, B.; Schaffer, A.; Casali, P.; Cerutti, A. DCs induce CD40-independent immunoglobulin class switching through BLYS and april. Nat. Immunol. 2002, 3, 822-829.
82. Yao, Y.; Richman, L.; Higgs, B.W.; Morehouse, C.A.; de los Reyes, M.; Brohawn, P.; Zhang, J.; White, B.; Coyle, A.J.; Kiener, P.A.; et al. Neutralization of interferon-α/β-inducible genes and downstream effect in a phase I trial of an anti-interferon-α monoclonal antibody in systemic lupus erythematosus. Arthritis Rheumatol. 2009, 60, 1785-1796.
83. Panchanathan, R.; Choubey, D. Murine baff expression is up-regulated by estrogen and interferons: Implications for sex bias in the development of autoimmunity. Mol. Immunol. 2013, 53, 15-23.
84. Batista, F.D.; Harwood, N.E. The who, how and where of antigen presentation to B cells. Nat. Rev. Immunol. 2009, 9, 15-27.
85. Fayette, J.; Dubois, B.; Vandenabeele, S.; Bridon, J.-M.; Vanbervliet, B.; Durand, I.; Banchereau, J.; Caux, C.; Brière, F. Human dendritic cells skew isotype switching of CD40-activated naive B cells towards IgA1 and IgA2. J. Exp. Med. 1997, 185, 1909-1918.
86. Wan, S.; Zhou, Z.; Duan, B.; Morel, L. Direct B cell stimulation by dendritic cells in a mouse model of lupus. Arthritis Rheumatol. 2008, 58, 1741-1750.
87. Poeck, H.; Wagner, M.; Battiany, J.; Rothenfusser, S.; Wellisch, D.; Hornung, V.; Jahrsdorfer, B.; Giese, T.; Endres, S.; Hartmann, G. Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Blood 2004, 103, 3058-3064.
88. Morva, A.; Lemoine, S.; Achour, A.; Pers, J.O.; Youinou, P.; Jamin, C. Maturation and function of human dendritic cells are regulated by B lymphocytes. Blood 2012, 119, 106-114.
89. Shaw, J.; Wang, Y.H.; Ito, T.; Arima, K.; Liu, Y.J. Plasmacytoid dendritic cells regulate B-cell growth and differentiation via CD70. Blood 2010, 115, 3051-3057.
90. Arens, R.; Nolte, M.A.; Tesselaar, K.; Heemskerk, B.; Reedquist, K.A.; van Lier, R.A.W.; van Oers, M.H.J. Signaling through CD70 regulates B cell activation and IgG production. J. Immunol. 2004, 173, 3901-3908.
91. Teichmann, L.L.; Ols, M.L.; Kashgarian, M.; Reizis, B.; Kaplan, D.H.; Shlomchik, M.J. Dendritic cells in lupus are not required for activation of T and B cells but promote their expansion, resulting in tissue damage. Immunity 2010, 33, 967-978.
92. Qian, L.; Qian, C.; Chen, Y.; Bai, Y.; Bao, Y.; Lu, L.; Cao, X. Regulatory dendritic cells program B cells to differentiate into CD19hiFcγiibhi regulatory B cells through IFN-beta and CD40l. Blood 2012, 120, 581-591.
93. Berggren, O.; Hagberg, N.; Weber, G.; Alm, G.V.; Rönnblom, L.; Eloranta, M.-L. B lymphocytes enhance interferon-α production by plasmacytoid dendritic cells. Arthritis Rheumatol. 2012, 64, 3409-3419.
94. Karni, A.; Abraham, M.; Monsonego, A.; Cai, G.; Freeman, G.J.; Hafler, D.; Khoury, S.J.; Weiner, H.L. Innate immunity in multiple sclerosis: Myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J. Immunol. 2006, 177, 4196-4202.
95. Tucci, M.; Calvani, N.; Richards, H.B.; Quatraro, C.; Silvestris, F. The interplay of chemokines and dendritic cells in the pathogenesis of lupus nephritis. Ann. N. Y. Acad. Sci. 2005, 1051, 421-432.
96. Decker, P.; Kotter, I.; Klein, R.; Berner, B.; Rammensee, H.G. Monocyte-derived dendritic cells over-express CD86 in patients with systemic lupus erythematosus. Rheumatology (Oxf.) 2006, 45, 1087-1095.
97. Jin, O.; Kavikondala, S.; Sun, L.; Fu, R.; Mok, M.-Y.; Chan, A.; Yeung, J.; Lau, C.-S. Systemic lupus erythematosus patients have increased number of circulating plasmacytoid dendritic cells, but decreased myeloid dendritic cells with deficient cd83 expression. Lupus 2008, 17, 654-662.
98. Kanakoudi-Tsakalidou, F.; Farmaki, E.; Tzimouli, V.; Taparkou, A.; Paterakis, G.; Trachana, M.; Pratsidou-Gertsi, P.; Nalbanti, P.; Papachristou, F. Simultaneous changes in serum HMGB1 and IFN-α levels and in LAIR-1 expression on plasmatoid dendritic cells of patients with juvenile SLE. New therapeutic options? Lupus 2014, 23, 305-312.
99. Hilliard, B.; Zizzo, G.; Ulas, M.; Linan, M.; Schreiter, J.; Cohen, P. Increased expression of mer tyrosine kinase in circulating dendritic cells and monocytes of lupus patients: Correlations with plasma interferon activity and steroid therapy. Arthritis Res. Ther. 2014, 16, R76.
100. Balanescu, A.; Radu, E.; Nat, R.; Regalia, T.; Bojinca, V.; Predescu, V.; Predeteanu, D. Co-stimulatory and adhesion molecules of dendritic cells in rheumatoid arthritis. J. Cell. Mol. Med. 2002, 6, 415-425.
101. Nieminen, J.K.; Vakkila, J.; Salo, H.M.; Ekström, N.; Härkönen, T.; Ilonen, J.; Knip, M.; Vaarala, O. Altered phenotype of peripheral blood dendritic cells in pediatric type 1 diabetes. Diabetes Care 2012, 35, 2303-2310.
102. Liu, Y.J. Ipc: Professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 2005, 23, 275-306.
103. Izaguirre, A.; Barnes, B.J.; Amrute, S.; Yeow, W.S.; Megjugorac, N.; Dai, J.; Feng, D.; Chung, E.; Pitha, P.M.; Fitzgerald-Bocarsly, P. Comparative analysis of IRF and IFN-alpha expression in human plasmacytoid and monocyte-derived dendritic cells. J. Leukoc. Biol. 2003, 74, 1125-1138.
104. Ito, T.; Kanzler, H.; Duramad, O.; Cao, W.; Liu, Y.J. Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells. Blood 2006, 107, 2423-2431.
105. Gottenberg, J.-E.; Cagnard, N.; Lucchesi, C.; Letourneur, F.; Mistou, S.; Lazure, T.; Jacques, S.; Ba, N.; Ittah, M.; Lepajolec, C.; et al. Activation of ifn pathways and plasmacytoid dendritic cell recruitment in target organs of primary sjögren's syndrome. Proc. Natl. Acad. Sci. USA 2006, 103, 2770-2775.
106. Ronnblom, L.E.; Alm, G.V.; Oberg, K. Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol. 1991, 30, 537-540.
107. Wilson, L.E.; Widman, D.; Dikman, S.H.; Gorevic, P.D. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin. Arthritis Rheum. 2002, 32, 163-173.
108. Kalkner, K.M.; Ronnblom, L.; Karlsson Parra, A.K.; Bengtsson, M.; Olsson, Y.; Oberg, K. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. QJM 1998, 91, 393-399.
109. Bennett, L.; Palucka, A.K.; Arce, E.; Cantrell, V.; Borvak, J.; Banchereau, J.; Pascual, V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 2003, 197, 711-723.
110. Piccinini, A.M.; Midwood, K.S. Dampening inflammation by modulating TLR signalling. Med. Inflamm. 2010, 2010.
111. Wen, Z.; Xu, L.; Chen, X.; Xu, W.; Yin, Z.; Gao, X.; Xiong, S. Autoantibody induction by DNA-containing immune complexes requires hmgb1 with the TLR2/microrna-155 pathway. J. Immunol. 2013, 190, 5411-5422.
112. Leadbetter, E.A.; Rifkin, I.R.; Hohlbaum, A.M.; Beaudette, B.C.; Shlomchik, M.J.; Marshak-Rothstein, A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and toll-like receptors. Nature 2002, 416, 603-607.
113. Doring, Y.; Manthey, H.D.; Drechsler, M.; Lievens, D.; Megens, R.T.; Soehnlein, O.; Busch, M.; Manca, M.; Koenen, R.R.; Pelisek, J.; et al. Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. Circulation 2012, 125, 1673-1683.
114. Sandgren, S.; Wittrup, A.; Cheng, F.; Jonsson, M.; Eklund, E.; Busch, S.; Belting, M. The human antimicrobial peptide LL-37 transfers extracellular DNA plasmid to the nuclear compartment of mammalian cells via lipid rafts and proteoglycan-dependent endocytosis. J. Biol. Chem. 2004, 279, 17951-17956.
115. Lande, R.; Gregorio, J.; Facchinetti, V.; Chatterjee, B.; Wang, Y.H.; Homey, B.; Cao, W.; Su, B.; Nestle, F.O.; Zal, T.; et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007, 449, 564-569.
116. Ganguly, D.; Chamilos, G.; Lande, R.; Gregorio, J.; Meller, S.; Facchinetti, V.; Homey, B.; Barrat, F.J.; Zal, T.; Gilliet, M. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J. Exp. Med. 2009, 206, 1983-1994.
117. Dombrowski, Y.; Schauber, J. Cathelicidin LL-37: A defense molecule with a potential role in psoriasis pathogenesis. Exp. Dermatol. 2012, 21, 327-330.
118. Gilliet, M.; Lande, R. Antimicrobial peptides and self-DNA in autoimmune skin inflammation. Curr. Opin. Immunol. 2008, 20, 401-407.
119. Sacre, K.; Criswell, L.A.; McCune, J.M. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res. Ther. 2012, 14, R155.
120. Ruiz-Irastorza, G.; Ramos-Casals, M.; Brito-Zeron, P.; Khamashta, M.A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review. Ann. Rheum. Dis. 2010, 69, 20-28.
121. Means, T.K.; Latz, E.; Hayashi, F.; Murali, M.R.; Golenbock, D.T.; Luster, A.D. Human lupus autoantibody-DNA complexes activate dcs through cooperation of CD32 and TLR9. J. Clin. Investig. 2005, 115, 407-417.
122. Bave, U.; Magnusson, M.; Eloranta, M.L.; Perers, A.; Alm, G.V.; Ronnblom, L. Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J. Immunol. 2003, 171, 3296-3302.
123. Lovgren, T.; Eloranta, M.L.; Kastner, B.; Wahren-Herlenius, M.; Alm, G.V.; Ronnblom, L. Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and sjogren's syndrome autoantigen-associated rna. Arthritis Rheumatol. 2006, 54, 1917-1927.
124. Mold, C.; Clos, T.W.D. C-reactive protein inhibits plasmacytoid dendritic cell interferon responses to autoantibody immune complexes. Arthritis Rheumatol. 2013, 65, 1891-1901.
125. Chen, D.Y.; Chen, Y.M.; Wen, M.C.; Hsieh, T.Y.; Hung, W.T.; Lan, J.L. The potential role of Th17 cells and Th17-related cytokines in the pathogenesis of lupus nephritis. Lupus 2012, 21, 1385-1396.
126. Rana, A.; Minz, R.W.; Aggarwal, R.; Anand, S.; Pasricha, N.; Singh, S. Gene expression of cytokines (TNF-alpha, IFN-gamma), serum profiles of IL-17 and IL-23 in paediatric systemic lupus erythematosus. Lupus 2012, 21, 1105-1112.
127. Wong, C.K.; Lit, L.C.; Tam, L.S.; Li, E.K.; Wong, P.T.; Lam, C.W. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: Implications for Th17-mediated inflammation in auto-immunity. Clin. Immunol. 2008, 127, 385-393.
128. Pan, W.C.; Chen, R.M.; Shen, Y.C.; Chen, C.C.; Ueng, Y.F. Suppressive effect of tobacco smoke extracts on oral p-glycoprotein function and its impact in smoke-induced insult to oral epidermal cells. Toxicol. Lett. 2009, 185, 116-123.
129. Steinman, R.M.; Hawiger, D.; Nussenzweig, M.C. Tolerogenic dendritic cells. Annu. Rev. Immunol. 2003, 21, 685-711.
130. Guerder, S.; Joncker, N.; Mahiddine, K.; Serre, L. Dendritic cells in tolerance and autoimmune diabetes. Curr. Opin. Immunol. 2013, 25, 670-675.
131. Gordon, J.R.; Ma, Y.; Churchman, L.; Gordon, S.A.; Dawicki, W. Regulatory dendritic cells for immunotherapy in immunologic diseases. Front. Immunol. 2014, 5, 7.
132. Van Brussel, I.; Lee, W.P.; Rombouts, M.; Nuyts, A.H.; Heylen, M.; de Winter, B.Y.; Cools, N.; Schrijvers, D.M. Tolerogenic dendritic cell vaccines to treat autoimmune diseases: Can the unattainable dream turn into reality? Autoimmun. Rev. 2014, 13, 138-150.
133. Raïch-Regué, D.; Glancy, M.; Thomson, A.W. Regulatory dendritic cell therapy: From rodents to clinical application. Immunol. Lett. 2014, 161, 216-221.
134. Inaba, K.; Inaba, M.; Romani, N.; Aya, H.; Deguchi, M.; Ikehara, S.; Muramatsu, S.; Steinman, R.M. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 1992, 176, 1693-1702.
135. Romani, N.; Gruner, S.; Brang, D.; Kämpgen, E.; Lenz, A.; Trockenbacher, B.; Konwalinka, G.; Fritsch, P.O.; Steinman, R.M.; Schuler, G. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 1994, 180, 83-93.
136. Moreau, A.; Varey, E.; Bouchet-Delbos, L.; Cuturi, M.-C. Cell therapy using tolerogenic dendritic cells in transplantation. Transplant. Res. 2012, 1, 13.
137. Klechevsky, E.; Banchereau, J. Human dendritic cells subsets as targets and vectors for therapy. Ann. N. Y. Acad. Sci. 2013, 1284, 24-30.
138. Everts, B.; Pearce, E.J. Metabolic control of dendritic cell activation and function: Recent advances and clinical implications. Front. Immunol. 2014, 5, 203.
139. Lewis, J.S.; Roche, C.; Zhang, Y.; Brusko, T.M.; Wasserfall, C.H.; Atkinson, M.; Clare-Salzler, M.J.; Keselowsky, B.G. Combinatorial delivery of immunosuppressive factors to dendritic cells using dual-sized microspheres. J. Mater. Chem. B Mater. Biol. Med. 2014, 2, 2562-2574.
140. Krawczyk, C.M.; Holowka, T.; Sun, J.; Blagih, J.; Amiel, E.; DeBerardinis, R.J.; Cross, J.R.; Jung, E.; Thompson, C.B.; Jones, R.G.; et al. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood 2010, 115, 4742-4749.
141. Ferreira, G.B.; Kleijwegt, F.S.; Waelkens, E.; Lage, K.; Nikolic, T.; Hansen, D.A.; Workman, C.T.; Roep, B.O.; Overbergh, L.; Mathieu, C. Differential protein pathways in 1,25-dihydroxyvitamin D3 and dexamethasone modulated tolerogenic human dendritic cells. J. Proteome Res. 2011, 11, 941-971.
142. Wobben, R.; Hüsecken, Y.; Lodewick, C.; Gibbert, K.; Fandrey, J.; Winning, S. Role of hypoxia inducible factor-1α for interferon synthesis in mouse dendritic cells. Biol. Chem. 2013, 394, 495.
143. Turnquist, H.R.; Raimondi, G.; Zahorchak, A.F.; Fischer, R.T.; Wang, Z.; Thomson, A.W. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J. Immunol. 2007, 178, 7018-7031.
144. Taner, T.; Hackstein, H.; Wang, Z.; Morelli, A.E.; Thomson, A.W. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce Ag-specific T cell regulation and prolong graft survival. Am. J. Transplant. 2005, 5, 228-236.
145. Fischer, R.T.; Turnquist, H.R.; Wang, Z.; Beer-Stolz, D.; Thomson, A.W. Rapamycin-conditioned, alloantigen-pulsed myeloid dendritic cells present donor MHC class I/peptide via the semi-direct pathway and inhibit survival of antigen-specific CD8+ T cells in vitro and in vivo. Transplant. Immunol. 2011, 25, 20-26.
146. Iruretagoyena, M.I.; Tobar, J.A.; Gonzalez, P.A.; Sepulveda, S.E.; Figueroa, C.A.; Burgos, R.A.; Hancke, J.L.; Kalergis, A.M. Andrographolide interferes with T cell activation and reduces experimental autoimmune encephalomyelitis in the mouse. J. Pharmacol. Exp. Ther. 2005, 312, 366-372.
147. Szatmari, I.; Torocsik, D.; Agostini, M.; Nagy, T.; Gurnell, M.; Barta, E.; Chatterjee, K.; Nagy, L. Ppargamma regulates the function of human dendritic cells primarily by altering lipid metabolism. Blood 2007, 110, 3271-3280.
148. Volchenkov, R.; Karlsen, M.; Jonsson, R.; Appel, S. Type 1 regulatory T cells and regulatory B cells induced by tolerogenic dendritic cells. Scand. J. Immunol. 2013, 77, 246-254.
149. Iruretagoyena, M.I.; Sepúlveda, S.E.; Lezana, J.P.; Hermoso, M.; Bronfman, M.; Gutiérrez, M.A.; Jacobelli, S.H.; Kalergis, A.M. Inhibition of nuclear factor-κB enhances the capacity of immature dendritic cells to induce antigen-specific tolerance in experimental autoimmune encephalomyelitis. J. Pharmacol. Exp. Ther. 2006, 318, 59-67.
150. Volchenkov, R.; Brun, J.; Jonsson, R.; Appel, S. In vitro suppression of immune responses using monocyte-derived tolerogenic dendritic cells from patients with primary sjogren's syndrome. Arthritis Res. Ther. 2013, 15, R114.
151. Xing, N.; ML, L.M.; Bachman, L.A.; McKean, D.J.; Kumar, R.; Griffin, M.D. Distinctive dendritic cell modulation by vitamin D(3) and glucocorticoid pathways. Biochem. Biophys. Res. Commun 2002, 297, 645-652.
152. Unger, W.W.J.; Laban, S.; Kleijwegt, F.S.; van der Slik, A.R.; Roep, B.O. Induction of treg by monocyte-derived dc modulated by vitamin D3 or dexamethasone: Differential role for PD-L1. Eur. J. Immunol. 2009, 39, 3147-3159.
153. Garcia-Gonzalez, P.; Morales, R.; Hoyos, L.; Maggi, J.; Campos, J.; Pesce, B.; Garate, D.; Larrondo, M.; Gonzalez, R.; Soto, L.; et al. A short protocol using dexamethasone and monophosphoryl lipid a generates tolerogenic dendritic cells that display a potent migratory capacity to lymphoid chemokines. J. Transl. Med. 2013, 11, 128.
154. Moser, M.; de Smedt, T.; Sornasse, T.; Tielemans, F.; Chentoufi, A.A.; Muraille, E.; van Mechelen, M.; Urbain, J.; Leo, O. Glucocorticoids down-regulate dendritic cell function in vitro and in vivo. Eur. J. Immunol. 1995, 25, 2818-2824.
155. Rea, D.; van Kooten, C.; van Meijgaarden, K.E.; Ottenhoff, T.H.; Melief, C.J.; Offringa, R. Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10. Blood 2000, 95, 3162-3167.
156. Farias, A.S.; Spagnol, G.S.; Bordeaux-Rego, P.; Oliveira, C.O.F.; Fontana, A.G.M.; de Paula, R.F.O.; Santos, M.P.A.; Pradella, F.; Moraes, A.S.; Oliveira, E.C.; et al. Vitamin D3 induces IDO+ tolerogenic DCs and enhances Treg, reducing the severity of EAE. CNS Neurosci. Ther. 2013, 19, 269-277.
157. Raϊch-Regué, D.; Grau-López, L.; Naranjo-Gómez, M.; Ramo-Tello, C.; Pujol-Borrell, R.; Martínez-Cáceres, E.; Borràs, F.E. Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients. Eur. J. Immunol. 2012, 42, 771-782.
158. Hackstein, H.; Taner, T.; Zahorchak, A.F.; Morelli, A.E.; Logar, A.J.; Gessner, A.; Thomson, A.W. Rapamycin inhibits IL-4-Induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003, 101, 4457-4463.
159. Fedoric, B.; Krishnan, R. Rapamycin downregulates the inhibitory receptors ILT2, ILT3, ILT4 on human dendritic cells and yet induces T cell hyporesponsiveness independent of Foxp3 induction. Immunol. Lett. 2008, 120, 49-56.
160. Hackstein, H.; Morelli, A.E.; Larregina, A.T.; Ganster, R.W.; Papworth, G.D.; Logar, A.J.; Watkins, S.C.; Falo, L.D.; Thomson, A.W. Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells. J. Immunol. 2001, 166, 7053-7062.
161. Buckland, M.; Jago, C.; Fazekesova, H.; George, A.; Lechler, R.; Lombardi, G. Aspirin modified dendritic cells are potent inducers of allo-specific regulatory T-cells. Int. Immunopharmacol. 2006, 6, 1895-1901.
162. Cai, D.T.; Ho, Y.H.S.; Chiow, K.H.; Wee, S.H.; Han, Y.; Peh, M.T.; Wong, S.H. Aspirin regulates snare protein expression and phagocytosis in dendritic cells. Mol. Membr. Biol. 2011, 28, 90-102.
163. Chauveau, C.; Remy, S.; Royer, P.J.; Hill, M.; Tanguy-Royer, S.; Hubert, F.X.; Tesson, L.; Brion, R.; Beriou, G.; Gregoire, M.; et al. Heme oxygenase-1 expression inhibits dendritic cell maturation and proinflammatory function but conserves IL-10 expression. Blood 2005, 106, 1694-1702.
164. Martin, E.; Capini, C.; Duggan, E.; Lutzky, V.P.; Stumbles, P.; Pettit, A.R.; O'Sullivan, B.; Thomas, R. Antigen-specific suppression of established arthritis in mice by dendritic cells deficient in NF-κB. Arthritis Rheumatol. 2007, 56, 2255-2266.
165. Ade, N.; Antonios, D.; Kerdine-Romer, S.; Boisleve, F.; Rousset, F.; Pallardy, M. NF-κB plays a major role in the maturation of human dendritic cells induced by NiSO4 but not by DNCB. Toxicol. Sci. 2007, 99, 488-501.
166. Ren, Y.; Yang, Y.; Yang, J.; Xie, R.; Fan, H. Tolerogenic dendritic cells modified by tacrolimus suppress CD4+ T-cell proliferation and inhibit collagen-induced arthritis in mice. Int. Immunopharmacol. 2014, 21, 247-254.
167. Sato, K.; Nagayama, H.; Tadokoro, K.; Juji, T.; Takahashi, T.A. Extracellular signal-regulated kinase, stress-activated protein kinase/c-Jun N-terminal kinase, and p38mapk are involved in IL-10-mediated selective repression of TNF-α-induced activation and maturation of human peripheral blood monocyte-derived dendritic cells. J. Immunol. 1999, 162, 3865-3872.
168. Knodler, A.; Schmidt, S.M.; Bringmann, A.; Weck, M.M.; Brauer, K.M.; Holderried, T.A.W.; Heine, A.K.; Grunebach, F.; Brossart, P. Post-transcriptional regulation of adapter molecules by IL-10 inhibits TLR-mediated activation of antigen-presenting cells. Leukemia 2008, 23, 535-544.
169. Velten, F.W.; Duperrier, K.; Bohlender, J.; Metharom, P.; Goerdt, S. A gene signature of inhibitory MHC receptors identifies a BDCA3+ subset of IL-10-induced dendritic cells with reduced allostimulatory capacity in vitro. Eur. J. Immunol. 2004, 34, 2800-2811.
170. Kubsch, S.; Graulich, E.; Knop, J.; Steinbrink, K. Suppressor activity of anergic T cells induced by IL-10-treated human dendritic cells: Association with IL-2- and CTLA-4-dependent G1 arrest of the cell cycle regulated by p27Kip1. Eur. J. Immunol. 2003, 33, 1988-1997.
171. Steinbrink, K.; Graulich, E.; Kubsch, S.; Knop, J.; Enk, A.H. CD4+ and CD8+ anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 2002, 99, 2468-2476.
172. Li, X.; Yang, A.; Huang, H.; Zhang, X.; Town, J.; Davis, B.; Cockcroft, D.W.; Gordon, J.R. Induction of type 2 T helper cell allergen tolerance by il-10-differentiated regulatory dendritic cells. Am. J. Respir. Cell Mol. Biol. 2010, 42, 190-199.
173. Lopez, M.N.; Pesce, B.; Kurte, M.; Perez, C.; Segal, G.; Roa, J.; Aguillon, J.C.; Mendoza-Naranjo, A.; Gesser, B.; Larsen, C.; et al. A synthetic peptide homologous to IL-10 functional domain induces monocyte differentiation to TGF-beta+ tolerogenic dendritic cells. Immunobiology 2011, 216, 1117-1126.
174. Ruffner, M.A.; Kim, S.H.; Bianco, N.R.; Francisco, L.M.; Sharpe, A.H.; Robbins, P.D. B7-1/2, but not PD-L1/2 molecules, are required on IL-10-treated tolerogenic DC and DC-derived exosomes for in vivo function. Eur. J. Immunol. 2009, 39, 3084-3090.
175. Jiang, H.; Hou, L.; Qiao, H.; Pan, S.; Zhou, B.; Liu, C.; Sun, X. Administration of tolerogenic dendritic cells induced by interleukin-10 prolongs rat splenic allograft survival. Transplant. Proc. 2004, 36, 3255-3259.
176. Thomas, D.C.; Wong, F.S.; Zaccone, P.; Green, E.A.; Wållberg, M. Protection of islet grafts through transforming growth factor-β-induced tolerogenic dendritic cells. Diabetes 2013, 62, 3132-3142.
177. Yan, F.; Cai, L.; Hui, Y.; Chen, S.; Meng, H.; Huang, Z. Tolerogenic dendritic cells suppress murine corneal allograft rejection by modulating CD28/CTLA-4 expression on regulatory T cells. Cell Biol. Int. 2014, 38, 835-848.
178. Segovia-Gamboa, N.; Rodríguez-Arellano, M.E.; Rangel-Cruz, R.; Sánchez-Díaz, M.; Ramírez-Reyes, J.C.; Faradji, R.; González-Domínguez, É.; Sánchez-Torres, C. Tolerogenic dendritic cells induce antigen-specific hyporesponsiveness in insulin- and glutamic acid decarboxylase 65-autoreactive T lymphocytes from type 1 diabetic patients. Clin. Immunol. 2014, 154, 72-83.
179. Torres-Aguilar, H.; Blank, M.; Kivity, S.; Misgav, M.; Luboshitz, J.; Pierangeli, S.S.; Shoenfeld, Y. Tolerogenic dendritic cells inhibit antiphospholipid syndrome derived effector/memory CD4+ T cell response to Β2GPI. Ann. Rheum. Dis. 2012, 71, 120-128.
180. D'Ambrosio, A.; Colucci, M.; Pugliese, O.; Quintieri, F.; Boirivant, M. Cholera toxin b subunit promotes the induction of regulatory T cells by preventing human dendritic cell maturation. J. Leukoc. Biol. 2008, 84, 661-668.
181. Chen, L.; Zheng, L.; He, W.; Qiu, M.; Gao, L.; Liu, J.; Huang, A. Cotransfection with IL-10 and TGF-beta1 into immature dendritic cells enhances immune tolerance in a rat liver transplantation model. Am. J. Physiol. Gastrointest. Liver Physiol. 2014, 306, G575-G581.
182. Li, R.; Zheng, X.; Popov, I.; Zhang, X.; Wang, H.; Suzuki, M.; Necochea-Campion, R.D.; French, P.W.; Chen, D.; Siu, L.; et al. Gene silencing of IL-12 in dendritic cells inhibits autoimmune arthritis. J. Transl. Med. 2012, 10, 19.
183. Zheng, X.; Suzuki, M.; Ichim, T.E.; Zhang, X.; Sun, H.; Zhu, F.; Shunnar, A.; Garcia, B.; Inman, R.D.; Min, W. Treatment of autoimmune arthritis using RNA interference-modulated dendritic cells. J. Immunol. 2010, 184, 6457-6464.
184. Kalantari, T.; Karimi, M.H.; Ciric, B.; Yan, Y.; Rostami, A.; Kamali-Sarvestani, E. Tolerogenic dendritic cells produced by lentiviral-mediated CD40- and IL-23p19-specific shRNA can ameliorate experimental autoimmune encephalomyelitis by suppressing Th17 cells. Clin. Exp. Immunol. 2014, 176, 180-189.
185. Ma, L.; Qian, S.; Liang, X.; Wang, L.; Woodward, J.E.; Giannoukakis, N.; Robbins, P.D.; Bertera, S.; Trucco, M.; Fung, J.J.; et al. Prevention of diabetes in nod mice by administration of dendritic cells deficient in nuclear transcription factor-κB activity. Diabetes 2003, 52, 1976-1985.
186. Machen, J.; Harnaha, J.; Lakomy, R.; Styche, A.; Trucco, M.; Giannoukakis, N. Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. J. Immunol. 2004, 173, 4331-4341.
187. Hackstein, H.; Taner, T.; Logar, A.J.; Thomson, A.W. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood 2002, 100, 1084-1087.
188. Leung, D.Y.M.; Bloom, J.W. Update on glucocorticoid action and resistance. J. Allergy Clin. Immunol. 2003, 111, 3-22.
189. Harry, R.A.; Anderson, A.E.; Isaacs, J.D.; Hilkens, C.M.U. Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann. Rheum. Dis. 2010, 69, 2042-2050.
190. Chiurchiù, V.; Cencioni, M.T.; Bisicchia, E.; de Bardi, M.; Gasperini, C.; Borsellino, G.; Centonze, D.; Battistini, L.; Maccarrone, M. Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis. Ann. Neurol. 2013, 73, 626-636.
191. Gross, C.C.; Jonuleit, H.; Wiendl, H. Fulfilling the dream: Tolerogenic dendritic cells to treat multiple sclerosis. Eur. J. Immunol. 2012, 42, 569-572.
192. Švajger, U.; Vidmar, A.; Jeras, M. Niflumic acid renders dendritic cells tolerogenic and up-regulates inhibitory molecules ilt3 and ilt4. Int. Immunopharmacol. 2008, 8, 997-1005.
193. Stallone, G.; Pontrelli, P.; Infante, B.; Gigante, M.; Netti, G.S.; Ranieri, E.; Grandaliano, G.; Gesualdo, L. Rapamycin induces ILT3highILT4high dendritic cells promoting a new immunoregulatory pathway. Kidney Int. 2014, 85, 888-897.
194. Ko, H.; Hambly, B.D.; Eris, J.M.; Levidiotis, V.; Wyburn, K.; Wu, H.; Chadban, S.J.; Yin, J.L. Dentritic cell derived IL-18 production is inhibited by rapamycin and sanglifehrin A, but not cyclosporine A. Transplant. Immunol. 2008, 20, 99-105.
195. Tardif, V.; Riquelme, S.A.; Remy, S.; Carreño, L.J.; Cortés, C.M.; Simon, T.; Hill, M.; Louvet, C.; Riedel, C.A.; Blancou, P.; et al. Carbon monoxide decreases endosome-lysosome fusion and inhibits soluble antigen presentation by dendritic cells to T cells. Eur. J. Immunol. 2013, 43, 2832-2844.
196. Simon, T.; Pogu, S.; Tardif, V.; Rigaud, K.; Rémy, S.; Piaggio, E.; Bach, J.-M.; Anegon, I.; Blancou, P. Carbon monoxide-treated dendritic cells decrease β1-integrin induction on cd8+ T cells and protect from type 1 diabetes. Eur. J. Immunol. 2013, 43, 209-218.
197. O'Neill, L.A.J. Toll-like receptor signal transduction and the tailoring of innate immunity: A role for mal? Trends Immunol. 2002, 23, 296-300.
198. Thomas, R.; Street, S.; Ramnoruth, N.; Pahau, H.; Law, S.; Brunck, M.; Hyde, C.; O'Sullivan, B.; Capini, C.; Tran, A.; et al. Feasibility, safety and clinical effects of single intradermal administration of autologous tolerising dendritic cells exposed to citrullinated peptides in patients with rheumatoid arthritis. Arthritis Rheumatol. 2011, 63, 2430.
199. Hackstein, H.; Thomson, A.W. Dendritic cells: Emerging pharmacological targets of immunosuppressive drugs. Nat. Rev. Immunol. 2004, 4, 24-35.
200. Llanos, C.; Mackern-Oberti, J.P.; Vega, F.; Jacobelli, S.H.; Kalergis, A.M. Tolerogenic dendritic cells as a therapy for treating lupus. Clin. Immunol. 2013, 148, 237-245.
201. Ding, Y.; Chen, D.; Tarcsafalvi, A.; Su, R.; Qin, L.; Bromberg, J.S. Suppressor of cytokine signaling 1 inhibits IL-10-mediated immune responses. J. Immunol. 2003, 170, 1383-1391.
202. Murray, P.J. Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. Curr. Opin. Pharmacol. 2006, 6, 379-386.
203. Figueroa-Vega, N.; Galindo-Rodríguez, G.; Bajaña, S.; Portales-Pérez, D.; Abud-Mendoza, C.; Sánchez-Torres, C.; González-Amaro, R. Phenotypic analysis of IL-10-treated, monocyte-derived dendritic cells in patients with systemic lupus erythematosus. Scand. J. Immunol. 2006, 64, 668-676.
204. Carreno, L.J.; Riedel, C.A.; Kalergis, A.M. Induction of tolerogenic dendritic cells by NF-kappaB blockade and FCγ receptor modulation. Methods Mol. Biol. 2010, 677, 339-353.
205. Zhou, Z.; Li, W.; Song, Y.; Wang, L.; Zhang, K.; Yang, J.; Zhang, W.; Su, H.; Zhang, Y. Growth differentiation factor-15 suppresses maturation and function of dendritic cells and inhibits tumor-specific immune response. PLoS One 2013, 8, e78618.
206. Bimczok, D.; Rau, H.; Wundrack, N.; Naumann, M.; Rothkötter, H.-J.; McCullough, K.; Summerfield, A. Cholera toxin promotes the generation of semi-mature porcine monocyte-derived dendritic cells that are unable to stimulate T cells. Vet. Res. 2007, 38, 597-612.
207. Pauley, K.; Cha, S. Rnai therapeutics in autoimmune disease. Pharmaceuticals 2013, 6, 287-294.
208. Apparailly, F.; Jorgensen, C. SiRNA-based therapeutic approaches for rheumatic diseases. Nat. Rev. Rheumatol. 2013, 9, 56-62.
209. Mathieu, P.; Chauveau, C.; Bouchet, D.; Guillot, C.; Tesson, L.; Anegon, I. Genetic engineering in allotransplantation of vascularized organs. Curr. Gene Ther. 2002, 2, 9-21.
210. Zheng, X.; Suzuki, M.; Zhang, X.; Ichim, T.; Zhu, F.; Ling, H.; Shunnar, A.; Wang, M.; Garcia, B.; Inman, R.; et al. RNAi-mediated CD40-CD154 interruption promotes tolerance in autoimmune arthritis. Arthritis Res. Ther. 2010, 12, R13.
211. Ferenbach, D.A.; Ramdas, V.; Spencer, N.; Marson, L.; Anegon, I.; Hughes, J.; Kluth, D.C. Macrophages expressing heme oxygenase-1 improve renal function in ischemia/reperfusion injury. Mol. Ther. 2010, 18, 1706-1713.
212. Qiu, T.; Zhu, H.-C.; Liu, X.-H.; Dong, W.-C.; Weng, X.-D.; Hu, C.-H.; Kuang, Y.-L.; Gao, R.-H.; Dan, C.; Tao, T. Lentiviral-mediated shrna against RelB induces the generation of tolerogenic dendritic cells. Int. Immunopharmacol. 2012, 12, 501-509.
213. Giannoukakis, N.; Phillips, B.; Finegold, D.; Harnaha, J.; Trucco, M. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 2011, 34, 2026-2032.
214. Giannoukakis, N. Interview: Immunoregulatory dendritic cells to treat autoimmunity are ready for the clinic. Immunotherapy 2013, 5, 919-921.
215. Johnson, L.; Jackson, D. Control of dendritic cell trafficking in lymphatics by chemokines. Angiogenesis 2014, 17, 335-345.
216. Scheinecker, C.; McHugh, R.; Shevach, E.M.; Germain, R.N. Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node. J. Exp. Med. 2002, 196, 1079-1090.
217. Tang, Q.; Adams, J.Y.; Tooley, A.J.; Bi, M.; Fife, B.T.; Serra, P.; Santamaria, P.; Locksley, R.M.; Krummel, M.F.; Bluestone, J.A. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat. Immunol. 2006, 7, 83-92.
218. Llanos, C.; Carreño, L.J.; Kalergis, A.M. Contribution of dendritic cell/T cell interactions to triggering and maintaining autoimmunity. Biol. Res. 2011, 44, 53-61.
219. Fife, B.T.; Pauken, K.E.; Eagar, T.N.; Obu, T.; Wu, J.; Tang, Q.; Azuma, M.; Krummel, M.F.; Bluestone, J.A. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat. Immunol. 2009, 10, 1185-1192.
220. Sercarz, E.E.; Lehmann, P.V.; Ametani, A.; Benichou, G.; Miller, A.; Moudgil, K. Dominance and crypticity of T cell antigenic determinants. Ann. Rev. Immunol. 1993, 11, 729-766.
221. Al-Hashimi, H.; Bhowmik, A. Generalised lymphadenopathy as the first manifestation of lupus nephritis. BMJ Case Rep. 2010, 2010, doi:10.1136/bcr.08.2009.2221.
222. Healy, L.J.; Collins, H.L.; Thompson, S.J. Systemic administration of tolerogenic dendritic cells ameliorates murine inflammatory arthritis. Open Rheumatol. J. 2008, 2, 71-80.
223. Ferreira, G.B.; Gysemans, C.A.; Demengeot, J.; da Cunha, J.P.M.C.M.; Vanherwegen, A.-S.; Overbergh, L.; van Belle, T.L.; Pauwels, F.; Verstuyf, A.; Korf, H.; et al. 1,25-dihydroxyvitamin d3 promotes tolerogenic dendritic cells with functional migratory properties in nod mice. J. Immunol. 2014, 192, 4210-4220.
224. Ahrens, E.T.; Flores, R.; Xu, H.; Morel, P.A. In vivo imaging platform for tracking immunotherapeutic cells. Nat. Biotechnol. 2005, 23, 983-987.
225. Kim, S.H.; Kim, S.; Evans, C.H.; Ghivizzani, S.C.; Oligino, T.; Robbins, P.D. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J. Immunol. 2001, 166, 3499-3505.
226. Anderson, A.E.; Swan, D.J.; Sayers, B.L.; Harry, R.A.; Patterson, A.M.; von Delwig, A.; Robinson, J.H.; Isaacs, J.D.; Hilkens, C.M.U. LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. J. Leukoc. Biol. 2009, 85, 243-250.
227. Cozzani, E.; Drosera, M.; Gasparini, G.; Parodi, A. Serology of lupus erythematosus: Correlation between immunopathological features and clinical aspects. Autoimmun. Dis. 2014, 2014, 13.
228. Caux, C.; Dezutter-Dambuyant, C.; Schmitt, D.; Banchereau, J. GM-CSF and TNF-alpha cooperate in the generation of dendritic langerhans cells. Nature 1992, 360, 258-261.
229. Hayden, H.; Friedl, J.; Dettke, M.; Sachet, M.; Hassler, M.; Dubsky, P.; Bachleitner-Hofmann, T.; Gnant, M.; Stift, A. Cryopreservation of monocytes is superior to cryopreservation of immature or semi-mature dendritic cells for dendritic cell-based immunotherapy. J. Immunother. 2009, 32, 638-654.
230. Strasser, E.F.; Eckstein, R. Optimization of leukocyte collection and monocyte isolation for dendritic cell culture. Transfus. Med. Rev. 2010, 24, 130-139.
231. Silveira, G.F.; Wowk, P.F.; Machado, A.M.B.; dos Santos, C.N.D.; Bordignon, J. Immature dendritic cells generated from cryopreserved human monocytes show impaired ability to respond to LPS and to induce allogeneic lymphocyte proliferation. PLoS One 2013, 8, e71291.
232. Galipeau, J. The mesenchymal stromal cells dilemma-Does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy 2013, 15, 2-8.
233. Giancola, R.; Bonfini, T.; Iacone, A. Cell therapy: cGMP facilities and manufacturing. Muscles Ligaments Tendons J. 2012, 2, 243-247.